CA2080472A1 - Infrared and near-infrared testing of blood constituents - Google Patents
Infrared and near-infrared testing of blood constituentsInfo
- Publication number
- CA2080472A1 CA2080472A1 CA002080472A CA2080472A CA2080472A1 CA 2080472 A1 CA2080472 A1 CA 2080472A1 CA 002080472 A CA002080472 A CA 002080472A CA 2080472 A CA2080472 A CA 2080472A CA 2080472 A1 CA2080472 A1 CA 2080472A1
- Authority
- CA
- Canada
- Prior art keywords
- light
- testing
- constituent
- intensity
- tympanic membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6814—Head
- A61B5/6815—Ear
- A61B5/6817—Ear canal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1491—Heated applicators
Abstract
An apparatus and method are disclosed for determining a level of a constituent such as glucose in a body fluid such as blood. The apparatus and method utilize a light generator (22) for generating a testing light of known intensity with the testing light including a wavelength absorbable by the constituent being measured.
The light generator (22) also generates a reference light of known intensity having a wavelength not absorbable by the constituent being measured. The testing light and reference light are directed towards a fluid containing an unknown concentration of a constituent. A light detector (30) is provided for measuring the intensity of the testing light and reference light being spectrally modified by the fluid. A light path distance measurer (28) is provided for measuring a distance of a light path travelled by the testing light and reference light. A circuit (32) is provided for calculating a level of the constituent in the fluid in response to a reduction in intensity of the testing light and reference light and in response to the measured distance.
The light generator (22) also generates a reference light of known intensity having a wavelength not absorbable by the constituent being measured. The testing light and reference light are directed towards a fluid containing an unknown concentration of a constituent. A light detector (30) is provided for measuring the intensity of the testing light and reference light being spectrally modified by the fluid. A light path distance measurer (28) is provided for measuring a distance of a light path travelled by the testing light and reference light. A circuit (32) is provided for calculating a level of the constituent in the fluid in response to a reduction in intensity of the testing light and reference light and in response to the measured distance.
Description
W~91/15990 PCT/~S91/02546 2 0 ~
....... . .
INFRARED AND NEAR INFRARED TESTING OF BLOOD CONSTITUENTS
I. :
,. . .
~: 5 BACKGROUND OF THE INVENTION
1. Field of the Invention.
This patent application pertains to an apparatus and method for testing blood constituents. More particularly, this application pertains to such apparatus and methods utilizing spectrophotometric ;l!J analysis of blood constituents.
,i . .
~` 2. Descrip~ion of the Prior Art.
~; The use of spectrophotometric methods to .`? 15 quantitatively determine the concentration of a blood constituent are known. For example, U.S. Patent No.
4,882,492 to Schlager teaches a non-invasive near- -~
. infrared measurement of blood analyte concentrations.
The Schlager patent is particularly directed to the measurement of blood glucose levels. The Schlager patent recognizes that certain wavelengths of light in ~ the near-infrared spectrum are absorbed by glucose.
-`' Nodulated light is directed against a tissue (shown as ~ an earlobe). The light is either passed through the ;~ 25 tissue or impinged on a skin surface. The light is ,~ spectrally modified in response to the amount of analyte (for example, glucose) in the blood and tissue. The spectrally modified light is split with one beam passed through a correlation cell. The other beam is passed through a reference cell. The intensity of the beams passing throuyh the correlation cell and the reference cell are compared to calculate a glucose concentration in the sample.
U.S. Patent 4,805,623 to Johsis teaches a spectral ~`
rh.o~o~.g~ic ~,o~ho~ fo - ~uantit:atlvel~ dg~9~m~in~in~ ~hs concentration of a component in human blood. The Jobsis method teaches various steps including the determination of an apparent effective path length for the light which is being absorbed by the constituent being measured.
.
., .
. ., , ,. . ,:
,,.,.~. , , . . , . .
~' : , : ,.
.. . . . .
W091/15990 PCT/US91/025f~
4~ ~ 2 ~
U.S. Patent 4,655,225 to Dahne et al. teaches a spectrophotometric method and apparatus for non-invasive ; testing. The Dahne patent is particularly directed to the measurement of blood glucose.
~ 5 U.S. Patents 4,014,321 and 3,958,560 to Narch teach -~ non~invasive glucose sensor systems which involve passing light through the cornea of the patient.
Notwithstanding the developments in the art, a need for an improved spectrophotometric measurement apparatus ~-~ 10 and method persists. For example, systems and methods which require the calculation of an apparent light pathway are susceptible to inaccuracy. Such a system is : shown in the aforementioned U.S. Patent 4,805,623.
Systems which have fixed dimensioned light pathways (for -~
example, U.S. Patent 4,014,321) are restricted in their use and practicality. It is also desirable to develop a ~i system and apparatus which can be used for non-invasive testing as well as invasive testing (for example, as a continuous monitor for testing blood glucose level ~ `
' 20 during surgery or insulin treatment). Further. it is desirable to develop a system which can be used in conjunction with a chemical emission system (such as a blood glucose monitoring system which controls an insulin administering apparatus). `
SUMMARY OF THE INVENTION ~ -According to a preferred embodiment of the present invention, an apparatus and method are disclosed for determining a level of a constituent such as glucose in a body fluid such as blood. The apparatus and method comprises a light generator for generating a testing light of known intensity with the testing light including a wavelength absorbable by the constituent being measured. The testing light is directed toward the fluid. A light detector is provided for measuring an intensity of the testing light reflected from the '; .
` ' "'~
^ : , ' :. .
~f .
.~ , ,: , ~, :
,. .
W~91t1~990 PCT/US91/02546 2~g~ll7~
!
fluid. A light path distance measurer is provided for measuring a distance of a light path from the light ~; generator to the light detector via the fluid. A
~, circuit is provided for calculating a level of the constituent in the fluid in response to a reduction in ~:~ intensity of the testing light between the light generator and the light detector and in response to the ; measured distanca.
III. ;~
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. l is a schematic representation of the . apparatus of the present invention showing its use in an embodiment for measuring a constituent within blood vessels in a tympanic membrane;
Fig. 2 is a view of an apparatus according to the ;
. present invention for use in invasive testing for blood glucose; and Fig. 3 is a schematic view of a system using the apparatus of the present invention to control admission of a drug to a patient~
."~
IV.
.,~ DESCRIPTION OF A PREFERRED EMBODIMENT
~i 25 Referring now to Fig. l, a detailed description of the preferred embodiment of the present invention will s~ now be provided. In the embodiment shown, the present invention is shown for use in non-invasive testing for a particular blood constituent -- namely, blood glucose. ~;
` 30 Also, in the embodiment of Fig. l, the present invention is shown in use for measuring blood glucose in blood vessels in a tympanic membrane. While the illustrated ~ application is a preferred embodiment, it will be 1 appreciated that the salient features o~ the present invention are applicable to a wide variety of body constituents. For example, glucose as well as other body constituents could be measured in a plurality of ', ' ' .
, : .. .. . : .
.... . ~ , ' - ' , ' . '' ; , :
::: , , . . :
:~, . , ,: ' ' .~'~. ' ' ' ' .
W~91/15990 PCT/US91/02546 body fluids such as blood, crevicular fluid, and peritoneal fluid. The salient features of the invention, as will be more fully described include the measurement of an actual light path of a testing light containing a wavelength absorbable by the constituent to be measured and calculating a constituent level in response to the amount of absorption of the wavelength and in response to the measured light path distance.
; These and further salient features of the present invention shall now be more fully described.
- In Fi~. 1, the apparatus 10 is shown in use for measuring blood glucose within blood vessels of a tympanic membrane 12 in a human ear 14. (The apparatus ~` 10 is also suitable for veterinary uses.) In the ~
15 embodiment now being described, the apparatus 10 is non- ~-invasive (i.e., no penetration of body tissue is required).
The apparatus lO includes a distal end which carries a speculum 16. Speculum 16 is preferably disposable and is sized to be received within the auditory canal 18 of an ear 14. The speculum is selected to block the ~ ~ `
auditory canal 18 to prevent ambient light from entering the ear past the speculum 16. Accordingly, the speculum 16 closes the auditory canal 18 to define a closed ; 25 testing volume l9 between the speculum 16 and the tympanic membrane 12. The actual distance D between the source of light in the speculum 16 and the tympanic ; membrane 12 will vary with each use of the apparatus 10.
'd~ However, as will be more fully described, the present invention includes means for measuring the distance D.
i For reasons that will become apparent, the speculum 16 has a tip 20 which opposed the tympanic membrane 12 , upon insertion of the speculum into the auditory canal 18. The tip 20 is selected to pass certain predetermined light wavelengths (e.g. wavelengths which are absorbable by constituents which are to be measured).
-- .
-~ , i :;, . . .. , .... - , . . ...
i . .
~, ' - ?
,. . . .
WO~ 599n PCT/US91/02~
''"'" , 52~1gO4~2 In a preferred example of measuring glucose within the tympanic membrane 12, the tip 20 is selected to pass infrared and near-infrared light wavelengths. It will be appreciated that a speculum such as speculum 16 having an infrared and near-infrared transparent tip 20 is known in the art. An example of such is shown in ~` U.S. Patent 4,662,360. 5uch prior art speculums have been developed for use with tympanic thermometers. The speculums of such thermometers would be inserted within the auditory canal and would permit infrared radiation ~ generated by a tympanic membrane to pass through the tip 'i of the speculum toward infrared radiation detecting apparatus contained within the speculum. With such prior art apparatus, a healthcare provider can measure ``~ 15 body temperature by detecting infrared radiation emitted from the tympanic membrane. Examples of complete apparatus for measuring body temperature from ~he , tympanic membrane are shown in U.S. Patent Nos.
'~ 4,602,642; 3,949,740; 3,878,836 and 4,790,324.
;~ 20 The pr~sent invention contemplates the generation of a te~ting light (including visible or non-visible wavelengths) which includes a wavelength absorbable by ~t3, the constituent to be measured (for example, blood glucose~. Shown schematically in Fig. l, the present invention includes a generator 22 of near-infrared and ~, infrared light sources. Generator 22 may be a lasing ~ -! diode or a broad band light source with a filter.
~ The generator 22 is selected to generate a testing ; light of known intensity which includes a wavelength ' 30 absorbable by the constituent to be tested. The , generator 22 also includes means for generating one or -~, more reference lights of known intensity having a wavelength which is not absorbable by the constituent to ' ~e measured. Also, for reasons that will ~e aescri~ed, the generator 22 includes means for generating infrared radiation of a heating wavelength selected to be ,, .
, ~
'-" . ' ' ~ ' . . ~. .:
,, " . . .. . . ..
, , .
~ ,'~ . " ` ' ' ' .
W~ 99~ PCT/US91/02546 directed for the purpose of warming the tympanic ; membrane 12 and volume l9.
A fiber optic cable 24 is passed from the generator 22 into the speculum 16 to be directed toward and oppose -~i 5 the tympanic membrane 12 upon insertion of the speculum 16 into the auditory canal 18. An alternative to using cable 24 would be for the generator 22 to be a light ~: diode within the speculum 16.
The reader will note that the ~avelengths of the . lO testing light, the reference light and the infrared ^ heating radiation will all be passed by tip 20 toward : tympanic membrane 12. In the preferred embodiment, the . testing light will include a glucose sensitive wavelength of about 500 to about 4000 wave numbers (cm~
l) The non-absorbable reference light will have a `~ preferred wavelength of about the same wavelength (e.g. .
i an absorbable wavelength of 1040 wave numbers and a non- ~
. absorbable wavelength of 1150 wave numbers). :
If it is desirable to test for constituents in addition to glucose, the generator 22 is simply selected to generate additional wavelengths selected for their - absorbability by the desired constituent. In the ;i schematic representation of Fig. 1, three optical paths ;
:-:. 25-27 are shown for directing the infrared and near-;: :
' 25 infrared radiation toward the tympanic membrane 12. In ^~i a preferred embodiment, all light signals will be passed ~::
through a single optical fiber 24 with the light signals ~; being multiplexed as will be described.
Including being coupled to light generator 22, the speculum 16 is coupled with a distance signal generator :~ 28. Distance signal generator 28 includes means for generating a signal for use in measuring the distance D
from the speculum 16 to the tympanic member 12. In a preferred embodiment, the distance slgnal generator 28 : .
is an ultrasonic generator wh:ich will measure the ' distance D through Doppler measurements. However, the ; present invention need not be limited to such an , -:,:: , , : : : : . . , .,; .: : ~ : : , ., , ; . : , - ' ' ' ' .
:" ~ : , : , :: . , ,:. : . :. . , . ~: :
, , ., - ,. .
,~ ', ~`,' " ' ' ", .: , ,, : , wos~ s~ PCT/US91/025~
O 7 2080~72 embodimen~. For example, light distance measuring techniques can also be employed. In such a case, the function~ of generators 22 and 28 can be merged with the light passing through fiber cable 24 also being utilized 5 to measure the distance D.
Finally, the distal end of the apparatus lO is connected to a photo diode and distance signal detector 30 which detects and measures the desired wavelengths : and signals reflected back from the tympanic membrane lO 12. Preferably, detector 30 will include means for detecting the temperature of volume l9. As previously ; described, tympanic temperature measurement is well known.
~; A circuit 32 (shown schematically in Fig. l) is I5 provided for calculating the level of the constituent in the blood in response to a reduction in intensity of the :~` testing light between the light generator 22 and the detector 30. The circuitry, through algorithms which will be de~cribed, compares the reduction in intensity ::
wi~h a reduction ln intensity of the non-absorbable wavelength and with the measured distance D. In ~:
response to the measured variables, the circuit 32 calculates the glucose level in the blood in the ~ tympanic membrane 12.
: 25 ~he circuit 32 includes a crystal oscillator 34 for driving the circuitry 32. Timing control circuitry 36 . is proYided for synchronizing the light generation and detec~ion of the apparatus lO. A multiplexer 38 is provided for multiplexing the signals and light pulses to be generated by generators 22 and 28.
j A signal preamplifier and demultiplexer 40 is - provided for receiving the detected signals from detector 30 and amplifying and demultiplexing into individual signals representing the intensity of the reflected absorbable and non-absorbable wavelengths, the : temperature of volume l9 and a signal to be used in calculat,ng distance D. In the pr_ferred embodiment, at .,: , :
, .
: . .
:.:.; ' :
, , ,. :. , , . :
, -, ., .~ - , .
,,. ' : . ,~, , . . . .
Wo9~ 990 ~ PCT/US91/025 8 '~
least two llght wavelengths (a wavelength absorbable by glucose and a reference wavelength not absorbable by glucose) are anticipated. However, in Fig. l, up to N
wavelengths are disclosed representing the utility of the present invention for testing for multiple blood constituents and having multiple reference wavelengths.
The first wavelength signal (for example, the testing light wavelength absorbable hy glucose) is admitted to a first decoder 42. Other signal wavelengths (such as the lO reference wavelength not absorbable by glucose) is `~
' admitted ~o additional decoders such as decoder 44 (labeled decoder N in Fig. l). A decoder 46 is also ~-. provided for decoding a signal representing the detection of the signal from the distance signal ` l5 generator 28. The decoders place the demultiplexed `r,i signals in proper sequence.
` All decoded signals are passed through filters 48-50 ~`~
~` (for noise filtration) and subsequently thraugh ' amplifiers 53-55. The amplified signals are passed `~ 20 through an analog-digital converter 56 to a microprocessor 58. Within the microprocessor 58, the signals are analyzed for the purposes of calculating the ~ -,j distance D and comparing the reduction in intensities ~' between the absorbable wavelength and the non-absorbable ~ .
wavelength for ~he purposes of determining the concentration of glucose within the blood in the tympanic membrane. A display 60 is provided for `
`' displaying to a healthcare provider the measured unknown i (i.e., the blood glucose concentration).
It will be appreciated that circùitry for generating multiplexed infrared light and near-infrared light is j well known and forms no part of this invention per se.
It will also be appreciated that circuitry and apparatus , for measuring distances (such as distance D) through either ultrasonic or light measurements (including Doppler measurements) are well known. Also, it will be ~ appreciated that apparatus and circuitry for detecting ?
" ' ' , ' . ~ , . . .
::. : , . , . , . , : ... "
;: ~ ~ . . . i - :
, . . , . . - , . .
:, ., , , : . , :
, ~ , . .. . . . . .. . .
, - , ' ' W~ 990 PCT/US91/02S~
2V~ l72 reflected light and demultiplexing signals are well known. Further, it will be appreciated that algorithms for calculating blood constituent levels in response to measured reductions in near-i.nfrared light intensities are well known.
The foregoing description identifies structure and - apparatus and a method of testing which eliminates certain of the disadvantages of the prior art. For example, multiple constituents may be tested through non-invasive testing by multiplexing a plurality of wavelengths which are selectively absorbable by the blood constituents to be measured. The present ~` invention also utilizes a warming circuit 62 for controlling the intensity of an infrared heater wavelength generated by generator 22. The warming circuitry 62 receives a signal from preamplifier 40 representing the temperature of volume 19 and tympanic membrane 12. In response to the signal, circuitry 62 controls generator 22 to heat and control the ~, 20 temperature of the tympanic membrane 12 and the auditory ~`~
~, canal 18 to a suficient elevated temperature to ensure that blood vessels within the tympanic membrane 12 remain open and that the measured absorption wavelengths -do not shift due to temperature change. As a result, the present apparatus and method have enhanced reliability over the prior art.
~ Importantly, the present invention measures the '5~ exact distance D that light is traveling from its source to the sample and back to a detection apparatus. It will be recognized that in spectrophotometric methods, the measurement of a distance of the light path is ;
essential since the reduction in intensity of the -absorbable wavelength is a function of the distance it is traveling as well as the concentration of the constituent to be measured. Prior art apparatus for ~', measuring blood glucose and other body constituents were not capable of measuring the actual light path distance il ,j . . .
~: ;,: , -: ,. ,: .
,. . , ,,, . ~ . .,: . . .:, : :
, . . ,:;:
, ,, ,. . : , :
... .
~ 91/l599~ PCT/~S91/0254S
9,~ o which could vary from test to test. Instead, prior art apparatus had a fixed light path distance (see, for example, U.S. Patent 4,014,321) or required the measurement of a so called "apparent" light path distance (see, for example, U.S. Patent 4,805,623).
The foregoing description disclosed two principle aspects of the present invention: (1) a comparison of reduction in intensity between an absorbable and a non-absorbable wavelength and (2) the calculation of the ` 10 precise light path distance traveled by the absorbable and non-absorbable wavelengths. The utilization of . .
these elements in combination with temperature control -of the test area result in a blood constituent measurement device which is particularly suitable for non-invasive testing. -In the preferred example, the apparatus is carried on the distal end of a device to be inserted within the auditory canal of an ear. This will provide a simple, quick and accurate testing of blood glucose in a ~-. 20 patient. However, certain of the salient features of ;~
~; the present invention (such as, the measurement of the precise distance and comparing reduction in intensity ~`
between non-absorbable and absorbable wavelengths) is also suitable for use in in vivo testing.
A particular structure for an in vivo application is i - shown in Fig. 2. In Fig. 2, a preferred apparatus 80 is l shown inserted within a blood vessel 82. The apparatus f 80, while shown in blood vessel 82, can be placed in any body cavity ~e.g., the peritoneal cavity).
The apparatus 80 includes a generally cylindrical membrane 84. Preferably, membrane 84 is selec~ed to be ~, permeable to the blood constituent to be measured. In the case of measuring blood glucose, membrane 84 is preferably dialysis tu~ing having a molecular weight cutoff slightly greater than the molecular weight of glucose (i.e. greater than 180.16). To illustrate the I permeability of membrane 84, holes 86 (shown greatly .
.,'' ,. ~ , ' ' ' . ; ' : . : ~ , . , , : :
.. .
, : . . .
,::, ~ , " . :
:.: ., . :
,; . . . .
: , , . ; ;
, . . .
W~9l/1599~ PCT/US91/02546 2~80~7~
exaggerated in size) are provided passing through the membrane 84.
First and second optical fibers 88 and 90 are provided inserted into opposite ends of membrane 84.
The fibers can be press, fit and sealed in membrane 84.
First optical fiber 88 has a concave end 89 opposing a ; convex end 91 of second fiber 90. Concave end 89 directs light toward end 91.
As in the previously described embodiment, multiplexed light wavelengths can be passed through fiber 88 toward fiber 90. The multiplexed wavelengths will include a wavelength absorbable by glucose and a non-absorbable wavelength. The absorbable and non-absorbable wavelengths pass through the membrane 84 - 15 between fibers 88 and 90 and are passed from fiber 90 to ~, the circuitry (not shown) such as that shown and described in the aforementioned embodiment. When .... .
. passing through the membrane 84, the intensities of both ;~ the absorbable and non-absorbable wavelengths will be ; 20 reduced. The absorbable wavelength will be particularly ~j reduced in response to the concentration of glucose within the membrane 84. By comparing the reduction in intensities between the absorbable and non-absorbable wavelength, the concentration of glucose within the i 25 membrane (and hence in the blood) can be determined if j the distance D~ between ends 89, 91 is known.
To measure distance D', an additional wavelength can be multiplexed with the absorbable and non-absorbable wavélength. The additional wavelength is selected to be passed from fiber 88 toward fiber 90 and reflected ; back from fiber 90 as back reflection into fiber 88.
'''! Through Doppler measurement techniques, the reflected light can be utilized to measure the accurate distance D' between fibers 88 and 90. It will be appreciated that the phenomena of back reflection forms no part of ~`J this invention per se and can be accomplished through selecting particular wavelengths to reflect off of fiber . .
; .,,:, , .. ,- : ~
- : ' - : '.: :; ~ . :
" , . . . . ..
" :, . . . : ~, :, WO9~/1599~ PCT/US9~/02546 ~`~ 12 90 or through the additional use of partially reflective coatings on surface 9l. As a result of Doppler measuring the distancs D' between fibers 88 and 90, the present invention can compensate for distance varia~ions 5 between fibers 88 and-90 which may result from compression due to posture of the patient, thermal expansion, manufacturing tolerances and other causes.
The use of the in vivo apparatus 80 is particularly suitable for constantly monitoring the blood constituent ~;
- lO level of a p~tient. Continuous monitoring is desireable during surgical procedures. Also, continuous monitoring " permits feedback control of chemical admission to patients. For example, with reference to Fig. 3, it is schematically shown how the present invention can be ~- 15 utilized to control the admission of insulin to a patient. In Fig. 3, an insulin source lO0 is shown ~, connected via a delivery pump 102 to a patient 104. The s apparatus of the present invention 106 (which includes ; the apparatus 80 plus the circuitry of Fig. l or just 20 the entire apparatus lO of Fig. 1 ! is shown connected to the patient 104 to constantly monitor the blood glucose of the patient. The measured blood glucose level of the patient as monitored by the present invention 106 is ! utilized to control the action of the delivery pump 102 25 in order to maintain the patient's blood glucose within predetermined tolerances of a desired blood glucose '~ level.
Through the foregoing detailed description of the present invention, it has been shown how the objects of 30 the present invention have attained in a preferred manner. However, modifications and equivalents of the disclosed concepts, such as those which would readily `
occur to one skilled in the art, are intended to be include~ within the scope o~ the clalms OI the present 35 invention.
~' , ~' .
- , .
'~'' .' " ' :' ,,, ,~ ~ ,' , ......................... .;, ~ . ... .
....... . .
INFRARED AND NEAR INFRARED TESTING OF BLOOD CONSTITUENTS
I. :
,. . .
~: 5 BACKGROUND OF THE INVENTION
1. Field of the Invention.
This patent application pertains to an apparatus and method for testing blood constituents. More particularly, this application pertains to such apparatus and methods utilizing spectrophotometric ;l!J analysis of blood constituents.
,i . .
~` 2. Descrip~ion of the Prior Art.
~; The use of spectrophotometric methods to .`? 15 quantitatively determine the concentration of a blood constituent are known. For example, U.S. Patent No.
4,882,492 to Schlager teaches a non-invasive near- -~
. infrared measurement of blood analyte concentrations.
The Schlager patent is particularly directed to the measurement of blood glucose levels. The Schlager patent recognizes that certain wavelengths of light in ~ the near-infrared spectrum are absorbed by glucose.
-`' Nodulated light is directed against a tissue (shown as ~ an earlobe). The light is either passed through the ;~ 25 tissue or impinged on a skin surface. The light is ,~ spectrally modified in response to the amount of analyte (for example, glucose) in the blood and tissue. The spectrally modified light is split with one beam passed through a correlation cell. The other beam is passed through a reference cell. The intensity of the beams passing throuyh the correlation cell and the reference cell are compared to calculate a glucose concentration in the sample.
U.S. Patent 4,805,623 to Johsis teaches a spectral ~`
rh.o~o~.g~ic ~,o~ho~ fo - ~uantit:atlvel~ dg~9~m~in~in~ ~hs concentration of a component in human blood. The Jobsis method teaches various steps including the determination of an apparent effective path length for the light which is being absorbed by the constituent being measured.
.
., .
. ., , ,. . ,:
,,.,.~. , , . . , . .
~' : , : ,.
.. . . . .
W091/15990 PCT/US91/025f~
4~ ~ 2 ~
U.S. Patent 4,655,225 to Dahne et al. teaches a spectrophotometric method and apparatus for non-invasive ; testing. The Dahne patent is particularly directed to the measurement of blood glucose.
~ 5 U.S. Patents 4,014,321 and 3,958,560 to Narch teach -~ non~invasive glucose sensor systems which involve passing light through the cornea of the patient.
Notwithstanding the developments in the art, a need for an improved spectrophotometric measurement apparatus ~-~ 10 and method persists. For example, systems and methods which require the calculation of an apparent light pathway are susceptible to inaccuracy. Such a system is : shown in the aforementioned U.S. Patent 4,805,623.
Systems which have fixed dimensioned light pathways (for -~
example, U.S. Patent 4,014,321) are restricted in their use and practicality. It is also desirable to develop a ~i system and apparatus which can be used for non-invasive testing as well as invasive testing (for example, as a continuous monitor for testing blood glucose level ~ `
' 20 during surgery or insulin treatment). Further. it is desirable to develop a system which can be used in conjunction with a chemical emission system (such as a blood glucose monitoring system which controls an insulin administering apparatus). `
SUMMARY OF THE INVENTION ~ -According to a preferred embodiment of the present invention, an apparatus and method are disclosed for determining a level of a constituent such as glucose in a body fluid such as blood. The apparatus and method comprises a light generator for generating a testing light of known intensity with the testing light including a wavelength absorbable by the constituent being measured. The testing light is directed toward the fluid. A light detector is provided for measuring an intensity of the testing light reflected from the '; .
` ' "'~
^ : , ' :. .
~f .
.~ , ,: , ~, :
,. .
W~91t1~990 PCT/US91/02546 2~g~ll7~
!
fluid. A light path distance measurer is provided for measuring a distance of a light path from the light ~; generator to the light detector via the fluid. A
~, circuit is provided for calculating a level of the constituent in the fluid in response to a reduction in ~:~ intensity of the testing light between the light generator and the light detector and in response to the ; measured distanca.
III. ;~
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. l is a schematic representation of the . apparatus of the present invention showing its use in an embodiment for measuring a constituent within blood vessels in a tympanic membrane;
Fig. 2 is a view of an apparatus according to the ;
. present invention for use in invasive testing for blood glucose; and Fig. 3 is a schematic view of a system using the apparatus of the present invention to control admission of a drug to a patient~
."~
IV.
.,~ DESCRIPTION OF A PREFERRED EMBODIMENT
~i 25 Referring now to Fig. l, a detailed description of the preferred embodiment of the present invention will s~ now be provided. In the embodiment shown, the present invention is shown for use in non-invasive testing for a particular blood constituent -- namely, blood glucose. ~;
` 30 Also, in the embodiment of Fig. l, the present invention is shown in use for measuring blood glucose in blood vessels in a tympanic membrane. While the illustrated ~ application is a preferred embodiment, it will be 1 appreciated that the salient features o~ the present invention are applicable to a wide variety of body constituents. For example, glucose as well as other body constituents could be measured in a plurality of ', ' ' .
, : .. .. . : .
.... . ~ , ' - ' , ' . '' ; , :
::: , , . . :
:~, . , ,: ' ' .~'~. ' ' ' ' .
W~91/15990 PCT/US91/02546 body fluids such as blood, crevicular fluid, and peritoneal fluid. The salient features of the invention, as will be more fully described include the measurement of an actual light path of a testing light containing a wavelength absorbable by the constituent to be measured and calculating a constituent level in response to the amount of absorption of the wavelength and in response to the measured light path distance.
; These and further salient features of the present invention shall now be more fully described.
- In Fi~. 1, the apparatus 10 is shown in use for measuring blood glucose within blood vessels of a tympanic membrane 12 in a human ear 14. (The apparatus ~` 10 is also suitable for veterinary uses.) In the ~
15 embodiment now being described, the apparatus 10 is non- ~-invasive (i.e., no penetration of body tissue is required).
The apparatus lO includes a distal end which carries a speculum 16. Speculum 16 is preferably disposable and is sized to be received within the auditory canal 18 of an ear 14. The speculum is selected to block the ~ ~ `
auditory canal 18 to prevent ambient light from entering the ear past the speculum 16. Accordingly, the speculum 16 closes the auditory canal 18 to define a closed ; 25 testing volume l9 between the speculum 16 and the tympanic membrane 12. The actual distance D between the source of light in the speculum 16 and the tympanic ; membrane 12 will vary with each use of the apparatus 10.
'd~ However, as will be more fully described, the present invention includes means for measuring the distance D.
i For reasons that will become apparent, the speculum 16 has a tip 20 which opposed the tympanic membrane 12 , upon insertion of the speculum into the auditory canal 18. The tip 20 is selected to pass certain predetermined light wavelengths (e.g. wavelengths which are absorbable by constituents which are to be measured).
-- .
-~ , i :;, . . .. , .... - , . . ...
i . .
~, ' - ?
,. . . .
WO~ 599n PCT/US91/02~
''"'" , 52~1gO4~2 In a preferred example of measuring glucose within the tympanic membrane 12, the tip 20 is selected to pass infrared and near-infrared light wavelengths. It will be appreciated that a speculum such as speculum 16 having an infrared and near-infrared transparent tip 20 is known in the art. An example of such is shown in ~` U.S. Patent 4,662,360. 5uch prior art speculums have been developed for use with tympanic thermometers. The speculums of such thermometers would be inserted within the auditory canal and would permit infrared radiation ~ generated by a tympanic membrane to pass through the tip 'i of the speculum toward infrared radiation detecting apparatus contained within the speculum. With such prior art apparatus, a healthcare provider can measure ``~ 15 body temperature by detecting infrared radiation emitted from the tympanic membrane. Examples of complete apparatus for measuring body temperature from ~he , tympanic membrane are shown in U.S. Patent Nos.
'~ 4,602,642; 3,949,740; 3,878,836 and 4,790,324.
;~ 20 The pr~sent invention contemplates the generation of a te~ting light (including visible or non-visible wavelengths) which includes a wavelength absorbable by ~t3, the constituent to be measured (for example, blood glucose~. Shown schematically in Fig. l, the present invention includes a generator 22 of near-infrared and ~, infrared light sources. Generator 22 may be a lasing ~ -! diode or a broad band light source with a filter.
~ The generator 22 is selected to generate a testing ; light of known intensity which includes a wavelength ' 30 absorbable by the constituent to be tested. The , generator 22 also includes means for generating one or -~, more reference lights of known intensity having a wavelength which is not absorbable by the constituent to ' ~e measured. Also, for reasons that will ~e aescri~ed, the generator 22 includes means for generating infrared radiation of a heating wavelength selected to be ,, .
, ~
'-" . ' ' ~ ' . . ~. .:
,, " . . .. . . ..
, , .
~ ,'~ . " ` ' ' ' .
W~ 99~ PCT/US91/02546 directed for the purpose of warming the tympanic ; membrane 12 and volume l9.
A fiber optic cable 24 is passed from the generator 22 into the speculum 16 to be directed toward and oppose -~i 5 the tympanic membrane 12 upon insertion of the speculum 16 into the auditory canal 18. An alternative to using cable 24 would be for the generator 22 to be a light ~: diode within the speculum 16.
The reader will note that the ~avelengths of the . lO testing light, the reference light and the infrared ^ heating radiation will all be passed by tip 20 toward : tympanic membrane 12. In the preferred embodiment, the . testing light will include a glucose sensitive wavelength of about 500 to about 4000 wave numbers (cm~
l) The non-absorbable reference light will have a `~ preferred wavelength of about the same wavelength (e.g. .
i an absorbable wavelength of 1040 wave numbers and a non- ~
. absorbable wavelength of 1150 wave numbers). :
If it is desirable to test for constituents in addition to glucose, the generator 22 is simply selected to generate additional wavelengths selected for their - absorbability by the desired constituent. In the ;i schematic representation of Fig. 1, three optical paths ;
:-:. 25-27 are shown for directing the infrared and near-;: :
' 25 infrared radiation toward the tympanic membrane 12. In ^~i a preferred embodiment, all light signals will be passed ~::
through a single optical fiber 24 with the light signals ~; being multiplexed as will be described.
Including being coupled to light generator 22, the speculum 16 is coupled with a distance signal generator :~ 28. Distance signal generator 28 includes means for generating a signal for use in measuring the distance D
from the speculum 16 to the tympanic member 12. In a preferred embodiment, the distance slgnal generator 28 : .
is an ultrasonic generator wh:ich will measure the ' distance D through Doppler measurements. However, the ; present invention need not be limited to such an , -:,:: , , : : : : . . , .,; .: : ~ : : , ., , ; . : , - ' ' ' ' .
:" ~ : , : , :: . , ,:. : . :. . , . ~: :
, , ., - ,. .
,~ ', ~`,' " ' ' ", .: , ,, : , wos~ s~ PCT/US91/025~
O 7 2080~72 embodimen~. For example, light distance measuring techniques can also be employed. In such a case, the function~ of generators 22 and 28 can be merged with the light passing through fiber cable 24 also being utilized 5 to measure the distance D.
Finally, the distal end of the apparatus lO is connected to a photo diode and distance signal detector 30 which detects and measures the desired wavelengths : and signals reflected back from the tympanic membrane lO 12. Preferably, detector 30 will include means for detecting the temperature of volume l9. As previously ; described, tympanic temperature measurement is well known.
~; A circuit 32 (shown schematically in Fig. l) is I5 provided for calculating the level of the constituent in the blood in response to a reduction in intensity of the :~` testing light between the light generator 22 and the detector 30. The circuitry, through algorithms which will be de~cribed, compares the reduction in intensity ::
wi~h a reduction ln intensity of the non-absorbable wavelength and with the measured distance D. In ~:
response to the measured variables, the circuit 32 calculates the glucose level in the blood in the ~ tympanic membrane 12.
: 25 ~he circuit 32 includes a crystal oscillator 34 for driving the circuitry 32. Timing control circuitry 36 . is proYided for synchronizing the light generation and detec~ion of the apparatus lO. A multiplexer 38 is provided for multiplexing the signals and light pulses to be generated by generators 22 and 28.
j A signal preamplifier and demultiplexer 40 is - provided for receiving the detected signals from detector 30 and amplifying and demultiplexing into individual signals representing the intensity of the reflected absorbable and non-absorbable wavelengths, the : temperature of volume l9 and a signal to be used in calculat,ng distance D. In the pr_ferred embodiment, at .,: , :
, .
: . .
:.:.; ' :
, , ,. :. , , . :
, -, ., .~ - , .
,,. ' : . ,~, , . . . .
Wo9~ 990 ~ PCT/US91/025 8 '~
least two llght wavelengths (a wavelength absorbable by glucose and a reference wavelength not absorbable by glucose) are anticipated. However, in Fig. l, up to N
wavelengths are disclosed representing the utility of the present invention for testing for multiple blood constituents and having multiple reference wavelengths.
The first wavelength signal (for example, the testing light wavelength absorbable hy glucose) is admitted to a first decoder 42. Other signal wavelengths (such as the lO reference wavelength not absorbable by glucose) is `~
' admitted ~o additional decoders such as decoder 44 (labeled decoder N in Fig. l). A decoder 46 is also ~-. provided for decoding a signal representing the detection of the signal from the distance signal ` l5 generator 28. The decoders place the demultiplexed `r,i signals in proper sequence.
` All decoded signals are passed through filters 48-50 ~`~
~` (for noise filtration) and subsequently thraugh ' amplifiers 53-55. The amplified signals are passed `~ 20 through an analog-digital converter 56 to a microprocessor 58. Within the microprocessor 58, the signals are analyzed for the purposes of calculating the ~ -,j distance D and comparing the reduction in intensities ~' between the absorbable wavelength and the non-absorbable ~ .
wavelength for ~he purposes of determining the concentration of glucose within the blood in the tympanic membrane. A display 60 is provided for `
`' displaying to a healthcare provider the measured unknown i (i.e., the blood glucose concentration).
It will be appreciated that circùitry for generating multiplexed infrared light and near-infrared light is j well known and forms no part of this invention per se.
It will also be appreciated that circuitry and apparatus , for measuring distances (such as distance D) through either ultrasonic or light measurements (including Doppler measurements) are well known. Also, it will be ~ appreciated that apparatus and circuitry for detecting ?
" ' ' , ' . ~ , . . .
::. : , . , . , . , : ... "
;: ~ ~ . . . i - :
, . . , . . - , . .
:, ., , , : . , :
, ~ , . .. . . . . .. . .
, - , ' ' W~ 990 PCT/US91/02S~
2V~ l72 reflected light and demultiplexing signals are well known. Further, it will be appreciated that algorithms for calculating blood constituent levels in response to measured reductions in near-i.nfrared light intensities are well known.
The foregoing description identifies structure and - apparatus and a method of testing which eliminates certain of the disadvantages of the prior art. For example, multiple constituents may be tested through non-invasive testing by multiplexing a plurality of wavelengths which are selectively absorbable by the blood constituents to be measured. The present ~` invention also utilizes a warming circuit 62 for controlling the intensity of an infrared heater wavelength generated by generator 22. The warming circuitry 62 receives a signal from preamplifier 40 representing the temperature of volume 19 and tympanic membrane 12. In response to the signal, circuitry 62 controls generator 22 to heat and control the ~, 20 temperature of the tympanic membrane 12 and the auditory ~`~
~, canal 18 to a suficient elevated temperature to ensure that blood vessels within the tympanic membrane 12 remain open and that the measured absorption wavelengths -do not shift due to temperature change. As a result, the present apparatus and method have enhanced reliability over the prior art.
~ Importantly, the present invention measures the '5~ exact distance D that light is traveling from its source to the sample and back to a detection apparatus. It will be recognized that in spectrophotometric methods, the measurement of a distance of the light path is ;
essential since the reduction in intensity of the -absorbable wavelength is a function of the distance it is traveling as well as the concentration of the constituent to be measured. Prior art apparatus for ~', measuring blood glucose and other body constituents were not capable of measuring the actual light path distance il ,j . . .
~: ;,: , -: ,. ,: .
,. . , ,,, . ~ . .,: . . .:, : :
, . . ,:;:
, ,, ,. . : , :
... .
~ 91/l599~ PCT/~S91/0254S
9,~ o which could vary from test to test. Instead, prior art apparatus had a fixed light path distance (see, for example, U.S. Patent 4,014,321) or required the measurement of a so called "apparent" light path distance (see, for example, U.S. Patent 4,805,623).
The foregoing description disclosed two principle aspects of the present invention: (1) a comparison of reduction in intensity between an absorbable and a non-absorbable wavelength and (2) the calculation of the ` 10 precise light path distance traveled by the absorbable and non-absorbable wavelengths. The utilization of . .
these elements in combination with temperature control -of the test area result in a blood constituent measurement device which is particularly suitable for non-invasive testing. -In the preferred example, the apparatus is carried on the distal end of a device to be inserted within the auditory canal of an ear. This will provide a simple, quick and accurate testing of blood glucose in a ~-. 20 patient. However, certain of the salient features of ;~
~; the present invention (such as, the measurement of the precise distance and comparing reduction in intensity ~`
between non-absorbable and absorbable wavelengths) is also suitable for use in in vivo testing.
A particular structure for an in vivo application is i - shown in Fig. 2. In Fig. 2, a preferred apparatus 80 is l shown inserted within a blood vessel 82. The apparatus f 80, while shown in blood vessel 82, can be placed in any body cavity ~e.g., the peritoneal cavity).
The apparatus 80 includes a generally cylindrical membrane 84. Preferably, membrane 84 is selec~ed to be ~, permeable to the blood constituent to be measured. In the case of measuring blood glucose, membrane 84 is preferably dialysis tu~ing having a molecular weight cutoff slightly greater than the molecular weight of glucose (i.e. greater than 180.16). To illustrate the I permeability of membrane 84, holes 86 (shown greatly .
.,'' ,. ~ , ' ' ' . ; ' : . : ~ , . , , : :
.. .
, : . . .
,::, ~ , " . :
:.: ., . :
,; . . . .
: , , . ; ;
, . . .
W~9l/1599~ PCT/US91/02546 2~80~7~
exaggerated in size) are provided passing through the membrane 84.
First and second optical fibers 88 and 90 are provided inserted into opposite ends of membrane 84.
The fibers can be press, fit and sealed in membrane 84.
First optical fiber 88 has a concave end 89 opposing a ; convex end 91 of second fiber 90. Concave end 89 directs light toward end 91.
As in the previously described embodiment, multiplexed light wavelengths can be passed through fiber 88 toward fiber 90. The multiplexed wavelengths will include a wavelength absorbable by glucose and a non-absorbable wavelength. The absorbable and non-absorbable wavelengths pass through the membrane 84 - 15 between fibers 88 and 90 and are passed from fiber 90 to ~, the circuitry (not shown) such as that shown and described in the aforementioned embodiment. When .... .
. passing through the membrane 84, the intensities of both ;~ the absorbable and non-absorbable wavelengths will be ; 20 reduced. The absorbable wavelength will be particularly ~j reduced in response to the concentration of glucose within the membrane 84. By comparing the reduction in intensities between the absorbable and non-absorbable wavelength, the concentration of glucose within the i 25 membrane (and hence in the blood) can be determined if j the distance D~ between ends 89, 91 is known.
To measure distance D', an additional wavelength can be multiplexed with the absorbable and non-absorbable wavélength. The additional wavelength is selected to be passed from fiber 88 toward fiber 90 and reflected ; back from fiber 90 as back reflection into fiber 88.
'''! Through Doppler measurement techniques, the reflected light can be utilized to measure the accurate distance D' between fibers 88 and 90. It will be appreciated that the phenomena of back reflection forms no part of ~`J this invention per se and can be accomplished through selecting particular wavelengths to reflect off of fiber . .
; .,,:, , .. ,- : ~
- : ' - : '.: :; ~ . :
" , . . . . ..
" :, . . . : ~, :, WO9~/1599~ PCT/US9~/02546 ~`~ 12 90 or through the additional use of partially reflective coatings on surface 9l. As a result of Doppler measuring the distancs D' between fibers 88 and 90, the present invention can compensate for distance varia~ions 5 between fibers 88 and-90 which may result from compression due to posture of the patient, thermal expansion, manufacturing tolerances and other causes.
The use of the in vivo apparatus 80 is particularly suitable for constantly monitoring the blood constituent ~;
- lO level of a p~tient. Continuous monitoring is desireable during surgical procedures. Also, continuous monitoring " permits feedback control of chemical admission to patients. For example, with reference to Fig. 3, it is schematically shown how the present invention can be ~- 15 utilized to control the admission of insulin to a patient. In Fig. 3, an insulin source lO0 is shown ~, connected via a delivery pump 102 to a patient 104. The s apparatus of the present invention 106 (which includes ; the apparatus 80 plus the circuitry of Fig. l or just 20 the entire apparatus lO of Fig. 1 ! is shown connected to the patient 104 to constantly monitor the blood glucose of the patient. The measured blood glucose level of the patient as monitored by the present invention 106 is ! utilized to control the action of the delivery pump 102 25 in order to maintain the patient's blood glucose within predetermined tolerances of a desired blood glucose '~ level.
Through the foregoing detailed description of the present invention, it has been shown how the objects of 30 the present invention have attained in a preferred manner. However, modifications and equivalents of the disclosed concepts, such as those which would readily `
occur to one skilled in the art, are intended to be include~ within the scope o~ the clalms OI the present 35 invention.
~' , ~' .
- , .
'~'' .' " ' :' ,,, ,~ ~ ,' , ......................... .;, ~ . ... .
Claims (40)
1. An apparatus for determining a level of a constituent in a body fluid, said apparatus comprising:
light generating means for generating a testing light of known intensity with said testing light including at least one wavelength absorbable by said constituent and directing said testing light toward said fluid;
light detecting means for measuring an intensity of said testing light reflected from said fluid;
light path measurement means for measuring a distance of a light path from said light generating means to said light detecting means via said fluid;
circuit means for calculating a level of said constituent in said fluid in response to a reduction in intensity of said testing light between said light generating means and said light detecting means and in response to said distance measured by said light path measurement means.
light generating means for generating a testing light of known intensity with said testing light including at least one wavelength absorbable by said constituent and directing said testing light toward said fluid;
light detecting means for measuring an intensity of said testing light reflected from said fluid;
light path measurement means for measuring a distance of a light path from said light generating means to said light detecting means via said fluid;
circuit means for calculating a level of said constituent in said fluid in response to a reduction in intensity of said testing light between said light generating means and said light detecting means and in response to said distance measured by said light path measurement means.
2. An apparatus according to claim 1 wherein said light generating means includes means for generating at least two wavelengths including said testing light and a reference light of known intensity having at least one wavelength not absorbable by said constituent, said light detecting means including means for measuring said testing light and said reference light reflected from said fluid and said circuit means including means for comparing said measured intensities and using said measured intensity of said reference light as a reference for determining the amount of said testing light absorbed by said constituent.
3. An apparatus according to claim 2 comprising means for multiplexing said testing and reference lights emitted from said light generating means.
4. An apparatus according to claim 1 comprising heating means for controlling a temperature of said fluid.
5. An apparatus according to claim 1 wherein said light generating means, said light detecting means and said light path measurement means are disposed at a distal end of a housing.
6. An apparatus according to claim 5 wherein said body fluid is contained within a tympanic membrane and wherein said housing is sized to be received within an auditory canal of an ear with said distal end opposing said tympanic membrane.
7. An apparatus according to claim 6 wherein said distal end includes a material selected to pass said absorbable wavelength.
8. An apparatus according to claim 7 wherein said absorbable wavelength is infrared.
9. An apparatus according to claim 1 wherein said testing light includes a plurality of wavelengths absorbable by a plurality of different constituents and wherein said circuit means includes means for separately calculating the level of each of said constituents in response to a measured intensity of each of said wavelengths reflected from said fluid.
10. An apparatus according to claim 6 wherein said housing includes means for blocking ambient light from entering said auditory canal and reaching said distal end.
11. An apparatus according to claim 1 wherein said fluid is blood.
12. An apparatus according to claim 11 wherein said constituent is glucose.
13. An apparatus according to claim 1 wherein said fluid is crevicular fluid.
14. An apparatus according to claim 13 wherein said constituent is glucose.
15. An apparatus according to claim 1 wherein said fluid is peritoneal fluid.
16. An apparatus according to claim 15 wherein said constituent is glucose.
17. An apparatus according to claim 1 comprising admitting means for admitting a chemical to a body with a level of said constituent in said body fluid changing in response to an amount of said chemical admitted to said body, control means connecting said circuit means to said admitting means for varying an amount of said chemical admitted to said body in response to a level of said constituent calculated by said circuit means.
18. An apparatus according to claim 6 comprising heating means for heating said tympanic member to a temperature sufficient for a fluid containing vessels in said tissue to be open.
19. An apparatus according to claim 6 comprising temperature detection means for detecting a temperature of said tympanic membrane.
20. An apparatus according to claim 19 comprising signal means indicating a measured temperature of said tympanic membrane has exceeded a maximum pre-determined temperature range.
21. An apparatus of determining a level of a blood constituent through non-invasive testing, said apparatus comprising:
light generating means for generating testing light of known intensity and including a wavelength absorbable by said constituent;
light detecting means for measuring an intensity of light;
housing means having a distal end for carrying said light generating means and said light detecting means with said distal end sized to be received within an auditory canal of an ear with said light generating means and said light detecting means opposing a tympanic membrane;
light path measurement means for measuring a distance of a light path from said light generating means to said light detecting means via said tympanic membrane;
circuit means for calculating a level of said constituent in blood within blood vessels of said tympanic membrane in response to a reduction of intensity of said testing light between said light generating means and said light detecting means and in response to said measured distance.
light generating means for generating testing light of known intensity and including a wavelength absorbable by said constituent;
light detecting means for measuring an intensity of light;
housing means having a distal end for carrying said light generating means and said light detecting means with said distal end sized to be received within an auditory canal of an ear with said light generating means and said light detecting means opposing a tympanic membrane;
light path measurement means for measuring a distance of a light path from said light generating means to said light detecting means via said tympanic membrane;
circuit means for calculating a level of said constituent in blood within blood vessels of said tympanic membrane in response to a reduction of intensity of said testing light between said light generating means and said light detecting means and in response to said measured distance.
22. An apparatus according to claim 21 wherein said light generating means includes means for generating at least two wavelengths including said testing light and the reference light having a wavelength not absorbable by said constituent, said light detecting means including means for measuring said testing light and said reference light reflected from said tympanic membrane, and in said circuit means including means for comparing said measured intensities and using said measured intensity of said reference light as a reference for determining the amount of said testing light absorbed by said constituent.
23. An apparatus according to claim 22 comprising means for multiplexing said testing and reference lights emitted from said light generating means.
24. An apparatus according to claim 21 comprising heating means for heating said tympanic membrane to a temperature sufficient for said blood vessels to be unrestricted.
25. An apparatus according to claim 21 wherein said distal end includes a material selected to pass said absorbable wavelength.
26. An apparatus according to claim 25 wherein said absorbable wavelength is infrared.
27. An apparatus according to claim 21 wherein said testing light includes a plurality of wavelengths absorbable by a plurality of different constituents wherein said circuit means includes means for separately calculating a level of each of said constituents in response to a measured intensity of each of said wavelengths reflected from said tissue.
28. An apparatus according to claim 21 wherein said housing includes means for blocking ambient light from entering said auditory canal and reaching said distal end.
29. An apparatus according to claim 21 wherein said constituent is blood glucose.
30. A method of non-invasive testing of a blood constituent utilizing light generating means for generating a testing light of known intensity and including a wavelength absorbable by said constituent, light detecting means for measuring an amount of light reflected from a tissue containing blood, light path measurement means for measuring a distance of a light path from said light generating means to said light detecting means via said tissue and circuit means for calculating a level of said constituent in said tissue in response to a reduction in intensity of said testing light said light generating means and said light detecting means and in response to said measured distance, said method including the steps of:
locating said light generating means in a location for light from said light generating means to be directed to a tympanic membrane and reflected back toward said light detecting means;
directing said testing light to said tympanic membrane;
measuring an intensity of said testing light reflected by said tympanic membrane;
measuring a distance of said light path from said light generating means to said light detecting means via said tympanic membrane; and calculating a level of said constituent by comparing said measured and known intensities and allowing for an effect of said measured distance.
locating said light generating means in a location for light from said light generating means to be directed to a tympanic membrane and reflected back toward said light detecting means;
directing said testing light to said tympanic membrane;
measuring an intensity of said testing light reflected by said tympanic membrane;
measuring a distance of said light path from said light generating means to said light detecting means via said tympanic membrane; and calculating a level of said constituent by comparing said measured and known intensities and allowing for an effect of said measured distance.
31. A method according to claim 30 wherein said method utilizes heating means for heating said tympanic membrane and said method includes the steps of heating said tympanic membrane to a temperature sufficient for blood vessels in said tympanic membrane to be unrestricted.
32. A method according to claim 30 wherein said light generating means includes means for generating at least two wavelengths including said testing light and a reference light of known intensity having a wavelength non-absorbable by said constituent, said light detecting means including means for measuring said testing light and said reference light reflected from said tympanic membrane and said circuit means including means for comparing said measured intensities and using said measured intensity of said reference light as a reference for determining the amount of said testing light absorbed by said constituent, said method including the step of directing said reference light towards the tympanic membrane and measuring an intensity of said reference light reflected off said tympanic membrane and calculating a level of said constituent by comparing a measured intensity of said reference light to a measured intensity of said testing light.
33. A method according to claim 33 comprising multiplexing said reference light and said testing light at said light generating means.
34. A method according to claim 30 wherein said constituent is glucose.
35. A method according to claim 30 wherein said wavelength of said testing light is infrared.
36. A method according to claim 30 wherein said testing light includes a plurality of wavelengths absorbable by a plurality of constituents and wherein said circuit means include the means for separately calculating the level of each of said constituents in response to a measured intensity of each of said wavelengths reflected from said tympanic membrane, said method including the steps of directing each of said plurality of wavelengths to said tympanic membrane and measuring an intensity of each wavelength reflected from said tympanic membrane and calculating the level of each of said constituents.
37. An apparatus for determining a level of a constituent in a body fluid, said apparatus comprising:
a first light transmitting member;
a second light transmitting member;
separation means for separating said first and second members by a separation distance with said first light transmitting member disposed to direct light to said second light transmitting member;
light generating means for generating a testing light of known intensity with said testing light including a wavelength absorbable by said constituent and directing said testing light to said first light transmitting member, said light generating means further including means for generating the reference light of known intensity and having a wavelength nonabsorbable by said constituent;
light detecting means for measuring an intensity of said testing light and said reference light in said second transmitting member;
light path measurement means for measuring a distance between said first and second light transmitting members;
circuit means for calculating a level of said constituent in a fluid between said first and second transmitting members in response to a reduction in intensities of said testing light and said reference light and in response to said distance measured by said light path measurement means.
a first light transmitting member;
a second light transmitting member;
separation means for separating said first and second members by a separation distance with said first light transmitting member disposed to direct light to said second light transmitting member;
light generating means for generating a testing light of known intensity with said testing light including a wavelength absorbable by said constituent and directing said testing light to said first light transmitting member, said light generating means further including means for generating the reference light of known intensity and having a wavelength nonabsorbable by said constituent;
light detecting means for measuring an intensity of said testing light and said reference light in said second transmitting member;
light path measurement means for measuring a distance between said first and second light transmitting members;
circuit means for calculating a level of said constituent in a fluid between said first and second transmitting members in response to a reduction in intensities of said testing light and said reference light and in response to said distance measured by said light path measurement means.
38. An apparatus according to claim 37 wherein said separation means includes means for defining an enclosed volume between said first and second light transmitting members with said separation means further including means for selectively passing into said volume a constituent from an exterior of said volume.
39. An apparatus according to claim 38 wherein said separation means includes a constituent permeable membrane.
40. An apparatus according to claim 38 wherein said first and second light transmitting members are optical fibers and said separation means is a permeable membrane tubing with said first and second light transmitting members fixed within opposite ends of said tubing.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/510,935 US5115133A (en) | 1990-04-19 | 1990-04-19 | Testing of body fluid constituents through measuring light reflected from tympanic membrane |
US510,935 | 1990-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2080472A1 true CA2080472A1 (en) | 1991-10-20 |
Family
ID=24032801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002080472A Abandoned CA2080472A1 (en) | 1990-04-19 | 1991-04-12 | Infrared and near-infrared testing of blood constituents |
Country Status (6)
Country | Link |
---|---|
US (2) | US5115133A (en) |
EP (1) | EP0525112A1 (en) |
JP (1) | JPH05506171A (en) |
AU (1) | AU7789391A (en) |
CA (1) | CA2080472A1 (en) |
WO (1) | WO1991015990A1 (en) |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9106672D0 (en) * | 1991-03-28 | 1991-05-15 | Abbey Biosystems Ltd | Method and apparatus for glucose concentration monitoring |
US5429129A (en) * | 1991-08-22 | 1995-07-04 | Sensor Devices, Inc. | Apparatus for determining spectral absorption by a specific substance in a fluid |
DE4128744C1 (en) * | 1991-08-29 | 1993-04-22 | Siemens Ag, 8000 Muenchen, De | |
US5370114A (en) * | 1992-03-12 | 1994-12-06 | Wong; Jacob Y. | Non-invasive blood chemistry measurement by stimulated infrared relaxation emission |
US5321492A (en) * | 1992-08-07 | 1994-06-14 | Miles Inc. | Dual function readhead for a reflectance instrument |
DE4314835A1 (en) * | 1993-05-05 | 1994-11-10 | Boehringer Mannheim Gmbh | Method and device for analysing glucose in a biological matrix |
IL107396A (en) * | 1992-11-09 | 1997-02-18 | Boehringer Mannheim Gmbh | Method and apparatus for analytical determination of glucose in a biological matrix |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
DE4337570A1 (en) * | 1993-11-04 | 1995-05-11 | Boehringer Mannheim Gmbh | Method for the analysis of glucose in a biological matrix |
JP3270916B2 (en) * | 1994-04-11 | 2002-04-02 | 日本光電工業株式会社 | Light sensor |
US5673692A (en) * | 1995-02-03 | 1997-10-07 | Biosignals Ltd. Co. | Single site, multi-variable patient monitor |
JP3326580B2 (en) * | 1995-05-08 | 2002-09-24 | 日本光電工業株式会社 | Biological tissue transmitted light sensor |
US5995860A (en) * | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US5657754A (en) * | 1995-07-10 | 1997-08-19 | Rosencwaig; Allan | Apparatus for non-invasive analyses of biological compounds |
US6240306B1 (en) | 1995-08-09 | 2001-05-29 | Rio Grande Medical Technologies, Inc. | Method and apparatus for non-invasive blood analyte measurement with fluid compartment equilibration |
US6212424B1 (en) | 1998-10-29 | 2001-04-03 | Rio Grande Medical Technologies, Inc. | Apparatus and method for determination of the adequacy of dialysis by non-invasive near-infrared spectroscopy |
US6624882B2 (en) | 1995-09-08 | 2003-09-23 | Integ, Inc. | Methods of sampling body fluid |
US5879367A (en) | 1995-09-08 | 1999-03-09 | Integ, Inc. | Enhanced interstitial fluid collection |
AU7015096A (en) * | 1995-09-08 | 1997-04-09 | Integ, Inc. | Body fluid sampler |
US6614522B1 (en) * | 1995-09-08 | 2003-09-02 | Integ, Inc. | Body fluid sampler |
US6517482B1 (en) | 1996-04-23 | 2003-02-11 | Dermal Therapy (Barbados) Inc. | Method and apparatus for non-invasive determination of glucose in body fluids |
US5890489A (en) * | 1996-04-23 | 1999-04-06 | Dermal Therapy (Barbados) Inc. | Method for non-invasive determination of glucose in body fluids |
US5666956A (en) * | 1996-05-20 | 1997-09-16 | Buchert; Janusz Michal | Instrument and method for non-invasive monitoring of human tissue analyte by measuring the body's infrared radiation |
WO1998001071A1 (en) * | 1996-07-08 | 1998-01-15 | Animas Corporation | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
US6689091B2 (en) * | 1996-08-02 | 2004-02-10 | Tuan Bui | Medical apparatus with remote control |
US5885245A (en) * | 1996-08-02 | 1999-03-23 | Sabratek Corporation | Medical apparatus with remote virtual input device |
US5895371A (en) * | 1996-08-27 | 1999-04-20 | Sabratek Corporation | Medical treatment apparatus and method |
US5871442A (en) | 1996-09-10 | 1999-02-16 | International Diagnostics Technologies, Inc. | Photonic molecular probe |
US6594510B2 (en) | 1996-09-10 | 2003-07-15 | Xoetronics Llc | Photonic molecular probe |
US6605057B2 (en) | 1996-10-24 | 2003-08-12 | Medtronic Ave, Inc. | Reinforced monorail balloon catheter |
US5823966A (en) * | 1997-05-20 | 1998-10-20 | Buchert; Janusz Michal | Non-invasive continuous blood glucose monitoring |
US6560352B2 (en) | 1999-10-08 | 2003-05-06 | Lumidigm, Inc. | Apparatus and method of biometric identification or verification of individuals using optical spectroscopy |
US7890158B2 (en) * | 2001-06-05 | 2011-02-15 | Lumidigm, Inc. | Apparatus and method of biometric determination using specialized optical spectroscopy systems |
US6628809B1 (en) | 1999-10-08 | 2003-09-30 | Lumidigm, Inc. | Apparatus and method for identification of individuals by near-infrared spectrum |
US6070093A (en) | 1997-12-02 | 2000-05-30 | Abbott Laboratories | Multiplex sensor and method of use |
US7587044B2 (en) | 1998-01-02 | 2009-09-08 | Cryptography Research, Inc. | Differential power analysis method and apparatus |
AU762922B2 (en) | 1998-02-04 | 2003-07-10 | Dermal Therapy (Barbados) Inc. | Method and apparatus for non-invasive determination of glucose in body fluids |
US6002953A (en) * | 1998-05-06 | 1999-12-14 | Optix Lp | Non-invasive IR transmission measurement of analyte in the tympanic membrane |
US7043287B1 (en) | 1998-05-18 | 2006-05-09 | Abbott Laboratories | Method for modulating light penetration depth in tissue and diagnostic applications using same |
US6662031B1 (en) | 1998-05-18 | 2003-12-09 | Abbott Laboratoies | Method and device for the noninvasive determination of hemoglobin and hematocrit |
US6241663B1 (en) | 1998-05-18 | 2001-06-05 | Abbott Laboratories | Method for improving non-invasive determination of the concentration of analytes in a biological sample |
US6662030B2 (en) | 1998-05-18 | 2003-12-09 | Abbott Laboratories | Non-invasive sensor having controllable temperature feature |
US6526298B1 (en) | 1998-05-18 | 2003-02-25 | Abbott Laboratories | Method for the non-invasive determination of analytes in a selected volume of tissue |
US6922576B2 (en) * | 1998-06-19 | 2005-07-26 | Becton, Dickinson And Company | Micro optical sensor device |
US6226082B1 (en) | 1998-06-25 | 2001-05-01 | Amira Medical | Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy |
US6535753B1 (en) | 1998-08-20 | 2003-03-18 | Microsense International, Llc | Micro-invasive method for painless detection of analytes in extra-cellular space |
US7098037B2 (en) | 1998-10-13 | 2006-08-29 | Inlight Solutions, Inc. | Accommodating subject and instrument variations in spectroscopic determinations |
US6157041A (en) * | 1998-10-13 | 2000-12-05 | Rio Grande Medical Technologies, Inc. | Methods and apparatus for tailoring spectroscopic calibration models |
US6441388B1 (en) | 1998-10-13 | 2002-08-27 | Rio Grande Medical Technologies, Inc. | Methods and apparatus for spectroscopic calibration model transfer |
US6424851B1 (en) | 1998-10-13 | 2002-07-23 | Medoptix, Inc. | Infrared ATR glucose measurement system (II) |
US6144444A (en) * | 1998-11-06 | 2000-11-07 | Medtronic Avecor Cardiovascular, Inc. | Apparatus and method to determine blood parameters |
US6398727B1 (en) | 1998-12-23 | 2002-06-04 | Baxter International Inc. | Method and apparatus for providing patient care |
US6231560B1 (en) | 1999-02-10 | 2001-05-15 | Baxter International Inc | Method and apparatus for automatically controlling the level of medication |
US6368563B1 (en) | 1999-03-12 | 2002-04-09 | Integ, Inc. | Collection well for body fluid tester |
US6080110A (en) * | 1999-04-19 | 2000-06-27 | Tel, Inc. | Heartbeat monitor for wearing during exercise |
US6442411B1 (en) | 1999-04-21 | 2002-08-27 | Optix, Lp | Method for improving calibration of an instrument for non-invasively measuring constituents in arterial blood |
US6816605B2 (en) | 1999-10-08 | 2004-11-09 | Lumidigm, Inc. | Methods and systems for biometric identification of individuals using linear optical spectroscopy |
AU1383301A (en) * | 1999-11-23 | 2001-06-04 | Forskningscenter Riso | A non-invasive method for the measurement of body fluid analytes |
JP4054853B2 (en) | 2000-10-17 | 2008-03-05 | 独立行政法人農業・食品産業技術総合研究機構 | Blood analysis using near infrared spectroscopy |
US6522903B1 (en) * | 2000-10-19 | 2003-02-18 | Medoptix, Inc. | Glucose measurement utilizing non-invasive assessment methods |
US6574490B2 (en) | 2001-04-11 | 2003-06-03 | Rio Grande Medical Technologies, Inc. | System for non-invasive measurement of glucose in humans |
US6862091B2 (en) | 2001-04-11 | 2005-03-01 | Inlight Solutions, Inc. | Illumination device and method for spectroscopic analysis |
US6865408B1 (en) | 2001-04-11 | 2005-03-08 | Inlight Solutions, Inc. | System for non-invasive measurement of glucose in humans |
US7126682B2 (en) * | 2001-04-11 | 2006-10-24 | Rio Grande Medical Technologies, Inc. | Encoded variable filter spectrometer |
US6983176B2 (en) | 2001-04-11 | 2006-01-03 | Rio Grande Medical Technologies, Inc. | Optically similar reference samples and related methods for multivariate calibration models used in optical spectroscopy |
EP1385423B1 (en) * | 2001-04-27 | 2007-11-21 | EyeSense AG | Kit for measuring blood glucose concentrations |
US20030040835A1 (en) * | 2001-04-28 | 2003-02-27 | Baxter International Inc. | A system and method for managing inventory of blood component collection soft goods in a blood component collection facility |
US6731961B2 (en) | 2001-11-09 | 2004-05-04 | Optiscan Biomedical Corp. | Method for transforming phase spectra to absorption spectra |
WO2003045235A1 (en) * | 2001-11-21 | 2003-06-05 | Optiscan Biomedical Corporation | Method for adjusting a blood analyte measurement |
US20030125662A1 (en) | 2002-01-03 | 2003-07-03 | Tuan Bui | Method and apparatus for providing medical treatment therapy based on calculated demand |
US6770883B2 (en) | 2002-01-30 | 2004-08-03 | Beckman Coulter, Inc. | Sample level detection system |
AU2003200359A1 (en) | 2002-02-11 | 2003-08-28 | Bayer Healthcare, Llc | Non-invasive System for the Determination of Analytes in Body Fluids |
GB0206792D0 (en) | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
US7050847B2 (en) | 2002-03-26 | 2006-05-23 | Stig Ollmar | Non-invasive in vivo determination of body fluid parameter |
US7027848B2 (en) | 2002-04-04 | 2006-04-11 | Inlight Solutions, Inc. | Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte |
WO2003100377A2 (en) * | 2002-05-27 | 2003-12-04 | Sensortec Limited | Improved detection system and method of detection |
US7620212B1 (en) | 2002-08-13 | 2009-11-17 | Lumidigm, Inc. | Electro-optical sensor |
CA2444211C (en) | 2002-10-11 | 2013-11-19 | Dermal Therapy (Barbados) Inc. | Determination of biological conditions using impedance measurements |
US7233817B2 (en) * | 2002-11-01 | 2007-06-19 | Brian Yen | Apparatus and method for pattern delivery of radiation and biological characteristic analysis |
US7627151B2 (en) * | 2003-04-04 | 2009-12-01 | Lumidigm, Inc. | Systems and methods for improved biometric feature definition |
US7347365B2 (en) * | 2003-04-04 | 2008-03-25 | Lumidigm, Inc. | Combined total-internal-reflectance and tissue imaging systems and methods |
US7394919B2 (en) | 2004-06-01 | 2008-07-01 | Lumidigm, Inc. | Multispectral biometric imaging |
US7460696B2 (en) | 2004-06-01 | 2008-12-02 | Lumidigm, Inc. | Multispectral imaging biometrics |
US7545963B2 (en) | 2003-04-04 | 2009-06-09 | Lumidigm, Inc. | Texture-biometrics sensor |
US7539330B2 (en) * | 2004-06-01 | 2009-05-26 | Lumidigm, Inc. | Multispectral liveness determination |
US7751594B2 (en) * | 2003-04-04 | 2010-07-06 | Lumidigm, Inc. | White-light spectral biometric sensors |
US7668350B2 (en) | 2003-04-04 | 2010-02-23 | Lumidigm, Inc. | Comparative texture analysis of tissue for biometric spoof detection |
AU2004227886A1 (en) * | 2003-04-04 | 2004-10-21 | Lumidigm, Inc. | Multispectral biometric sensor |
US20040225206A1 (en) * | 2003-05-09 | 2004-11-11 | Kouchnir Mikhail A. | Non-invasive analyte measurement device having increased signal to noise ratios |
SE0301718L (en) * | 2003-06-13 | 2005-02-11 | Atos Medical Ab | Method and device for determining body condition |
US20050007582A1 (en) * | 2003-07-07 | 2005-01-13 | Lumidigm, Inc. | Methods and apparatus for collection of optical reference measurements for monolithic sensors |
US7356365B2 (en) | 2003-07-09 | 2008-04-08 | Glucolight Corporation | Method and apparatus for tissue oximetry |
US20050043630A1 (en) * | 2003-08-21 | 2005-02-24 | Buchert Janusz Michal | Thermal Emission Non-Invasive Analyte Monitor |
WO2005020841A2 (en) * | 2003-08-25 | 2005-03-10 | Sarnoff Corporation | Monitoring using signals detected from auditory canal |
US7107088B2 (en) * | 2003-08-25 | 2006-09-12 | Sarnoff Corporation | Pulse oximetry methods and apparatus for use within an auditory canal |
US7263213B2 (en) | 2003-12-11 | 2007-08-28 | Lumidigm, Inc. | Methods and systems for estimation of personal characteristics from biometric measurements |
US20050137469A1 (en) * | 2003-12-17 | 2005-06-23 | Berman Herbert L. | Single detector infrared ATR glucose measurement system |
US7510849B2 (en) * | 2004-01-29 | 2009-03-31 | Glucolight Corporation | OCT based method for diagnosis and therapy |
US20050171413A1 (en) * | 2004-02-04 | 2005-08-04 | Medoptix, Inc. | Integrated device for non-invasive analyte measurement |
EP1718200B1 (en) * | 2004-02-05 | 2016-04-13 | Dermal Devices INC. | Apparatus for measuring blood glucose using sub-dermal body tissue impedance measurements |
US20050187525A1 (en) * | 2004-02-19 | 2005-08-25 | Hilgers Michael E. | Devices and methods for extracting bodily fluid |
KR20060129507A (en) * | 2004-03-06 | 2006-12-15 | 카리스토 메디컬, 아이엔씨. | Methods and devices for non-invasively measuring quantitative information of substances in living organisms |
US8229185B2 (en) * | 2004-06-01 | 2012-07-24 | Lumidigm, Inc. | Hygienic biometric sensors |
US7508965B2 (en) * | 2004-06-01 | 2009-03-24 | Lumidigm, Inc. | System and method for robust fingerprint acquisition |
US20110163163A1 (en) * | 2004-06-01 | 2011-07-07 | Lumidigm, Inc. | Multispectral barcode imaging |
US8343074B2 (en) * | 2004-06-30 | 2013-01-01 | Lifescan Scotland Limited | Fluid handling devices |
US7254429B2 (en) * | 2004-08-11 | 2007-08-07 | Glucolight Corporation | Method and apparatus for monitoring glucose levels in a biological tissue |
ITMI20041644A1 (en) * | 2004-08-11 | 2004-11-11 | Eni Spa | PROCEDURE FOR THE STORAGE OF SULFUR WITH ZERO EMISSION |
US8787630B2 (en) | 2004-08-11 | 2014-07-22 | Lumidigm, Inc. | Multispectral barcode imaging |
US8036727B2 (en) | 2004-08-11 | 2011-10-11 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
EP1874178A4 (en) | 2005-04-13 | 2009-12-09 | Glucolight Corp | Method for data reduction and calibration of an oct-based blood glucose monitor |
WO2006113476A2 (en) * | 2005-04-15 | 2006-10-26 | Bayer Healthcare Llc | Non-invasive system for measuring glucose in the body |
US7801338B2 (en) | 2005-04-27 | 2010-09-21 | Lumidigm, Inc. | Multispectral biometric sensors |
JP2006322841A (en) * | 2005-05-19 | 2006-11-30 | Shimadzu Corp | Spectrometry and spectrophotometer |
US20090270698A1 (en) * | 2005-10-21 | 2009-10-29 | Masahiko Shioi | Bioinformation measurement device |
WO2007049562A1 (en) | 2005-10-24 | 2007-05-03 | Matsushita Electric Industrial Co., Ltd. | Apparatus for measuring biological component concentration |
US9636035B2 (en) | 2005-12-14 | 2017-05-02 | Scibase Ab | Medical apparatus for determination of biological conditions using impedance measurements |
ES2400811T3 (en) | 2005-12-14 | 2013-04-12 | Scibase Ab | Diagnosis of a pathological state of the skin using impedance |
EP1820441A1 (en) * | 2006-02-16 | 2007-08-22 | Roche Diagnostics GmbH | Microneedle arrays with attenuated total reflection (ATR) sensor |
CN101400300A (en) * | 2006-03-10 | 2009-04-01 | 松下电器产业株式会社 | Instrument for measuring concentration of living body ingredient |
EP1905356A4 (en) * | 2006-03-10 | 2008-10-15 | Matsushita Electric Ind Co Ltd | Living body ingredient concentration measuring instrument |
US8355545B2 (en) * | 2007-04-10 | 2013-01-15 | Lumidigm, Inc. | Biometric detection using spatial, temporal, and/or spectral techniques |
CN101506826A (en) * | 2006-07-19 | 2009-08-12 | 光谱辨识公司 | Multibiometric multispectral imager |
US7995808B2 (en) * | 2006-07-19 | 2011-08-09 | Lumidigm, Inc. | Contactless multispectral biometric capture |
US8175346B2 (en) * | 2006-07-19 | 2012-05-08 | Lumidigm, Inc. | Whole-hand multispectral biometric imaging |
US7804984B2 (en) | 2006-07-31 | 2010-09-28 | Lumidigm, Inc. | Spatial-spectral fingerprint spoof detection |
US7801339B2 (en) | 2006-07-31 | 2010-09-21 | Lumidigm, Inc. | Biometrics with spatiospectral spoof detection |
US8652040B2 (en) * | 2006-12-19 | 2014-02-18 | Valencell, Inc. | Telemetric apparatus for health and environmental monitoring |
JP5109125B2 (en) * | 2007-03-14 | 2012-12-26 | 国立大学法人浜松医科大学 | In vivo component analyzer |
EP2120713A2 (en) * | 2007-03-21 | 2009-11-25 | Lumidigm, Inc. | Biometrics based on locally consistent features |
WO2009065586A2 (en) * | 2007-11-20 | 2009-05-28 | Mbr Optical Systems Gmbh & Co. Kg | Method and measuring device for collecting indicative signals relating to the concentration of a substance in an examination area, in particular from living tissue |
WO2009111542A2 (en) | 2008-03-04 | 2009-09-11 | Glucolight Corporation | Methods and systems for analyte level estimation in optical coherence tomography |
WO2009121392A1 (en) * | 2008-03-31 | 2009-10-08 | Scibase Ab | Method and device for non-invasive determination of the concentration of a substance in a body fluid |
CA2722616A1 (en) * | 2008-05-12 | 2009-11-19 | Cardio Art Technologies, Ltd. | Method and system for monitoring a health condition |
US20100246902A1 (en) * | 2009-02-26 | 2010-09-30 | Lumidigm, Inc. | Method and apparatus to combine biometric sensing and other functionality |
BR112012004177A2 (en) * | 2009-08-26 | 2016-03-29 | Lumidigm Inc | biometric method and system, system, method, object location, object discrimination, and background methods, and multifaceted prism |
US9261407B2 (en) * | 2009-11-02 | 2016-02-16 | Eric M. Lawson | Thermometer for determining the temperature of an animal's ear drum and method of using the same |
US8386800B2 (en) | 2009-12-04 | 2013-02-26 | Cryptography Research, Inc. | Verifiable, leak-resistant encryption and decryption |
US8570149B2 (en) | 2010-03-16 | 2013-10-29 | Lumidigm, Inc. | Biometric imaging using an optical adaptive interface |
US10213550B2 (en) | 2014-01-23 | 2019-02-26 | Covidien Lp | Systems and methods for monitoring clinical procedures using regional blood oxygen saturation |
US9867561B2 (en) | 2014-01-27 | 2018-01-16 | Covidien Lp | Systems and methods for determining whether regional oximetry sensors are properly positioned |
US9861317B2 (en) | 2014-02-20 | 2018-01-09 | Covidien Lp | Methods and systems for determining regional blood oxygen saturation |
KR102390874B1 (en) | 2014-10-29 | 2022-04-26 | 삼성전자주식회사 | Glucose measure apparatus and method of measuring glucose thereof |
US10328202B2 (en) | 2015-02-04 | 2019-06-25 | Covidien Lp | Methods and systems for determining fluid administration |
US10952682B2 (en) | 2015-07-19 | 2021-03-23 | Sanmina Corporation | System and method of a biosensor for detection of health parameters |
US9636457B2 (en) | 2015-07-19 | 2017-05-02 | Sanmina Corporation | System and method for a drug delivery and biosensor patch |
US10973470B2 (en) | 2015-07-19 | 2021-04-13 | Sanmina Corporation | System and method for screening and prediction of severity of infection |
US9788767B1 (en) | 2015-09-25 | 2017-10-17 | Sanmina Corporation | System and method for monitoring nitric oxide levels using a non-invasive, multi-band biosensor |
US10321860B2 (en) | 2015-07-19 | 2019-06-18 | Sanmina Corporation | System and method for glucose monitoring |
US10888280B2 (en) | 2016-09-24 | 2021-01-12 | Sanmina Corporation | System and method for obtaining health data using a neural network |
US10744261B2 (en) | 2015-09-25 | 2020-08-18 | Sanmina Corporation | System and method of a biosensor for detection of vasodilation |
US10750981B2 (en) | 2015-09-25 | 2020-08-25 | Sanmina Corporation | System and method for health monitoring including a remote device |
US10194871B2 (en) | 2015-09-25 | 2019-02-05 | Sanmina Corporation | Vehicular health monitoring system and method |
US10932727B2 (en) | 2015-09-25 | 2021-03-02 | Sanmina Corporation | System and method for health monitoring including a user device and biosensor |
US10736580B2 (en) | 2016-09-24 | 2020-08-11 | Sanmina Corporation | System and method of a biosensor for detection of microvascular responses |
US10874333B2 (en) | 2015-09-15 | 2020-12-29 | Massachusetts Institute Of Technology | Systems and methods for diagnosis of middle ear conditions and detection of analytes in the tympanic membrane |
US10945676B2 (en) | 2015-09-25 | 2021-03-16 | Sanmina Corporation | System and method for blood typing using PPG technology |
ES2575234B1 (en) * | 2015-09-30 | 2017-04-05 | Dispositivos No Invasivos Para Diagnosis, S.L. | Non-invasive insulin delivery team |
US10568515B2 (en) | 2016-06-21 | 2020-02-25 | Otonexus Medical Technologies, Inc. | Optical coherence tomography device for otitis media |
US10357161B1 (en) | 2017-05-31 | 2019-07-23 | Otonexus Medical Technologies, Inc. | Infrared otoscope for characterization of effusion |
EP3624679B1 (en) * | 2017-05-19 | 2023-09-13 | GlucoVista Inc. | Glucose concentration nir monitoring apparatuses and methods |
US10466783B2 (en) | 2018-03-15 | 2019-11-05 | Sanmina Corporation | System and method for motion detection using a PPG sensor |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2414747A (en) * | 1942-07-02 | 1947-01-21 | Harry M Kirschbaum | Method and apparatus for controlling the oxygen content of the blood of living animals |
US3054893A (en) * | 1959-04-06 | 1962-09-18 | Gen Railway Signal Co | Automatic car retarder control system |
US3054397A (en) * | 1959-11-05 | 1962-09-18 | Theodore H Benzinger | Method for measuring body temperature |
US3156117A (en) * | 1961-09-21 | 1964-11-10 | Theodor H Benzinger | Clinical ear thermometer |
US3282106A (en) * | 1963-01-28 | 1966-11-01 | Barnes Eng Co | Method of measuring body temperature |
US3463142A (en) * | 1966-07-05 | 1969-08-26 | Trw Inc | Blood content monitor |
FR1526973A (en) * | 1967-01-18 | 1968-05-31 | Device for photometry in any penetrable medium | |
DE2122655A1 (en) * | 1971-05-07 | 1972-11-30 | Max Planck Gesellschaft | Optical absorption device for determining the concentration of a component of a substance mixture |
US3949740A (en) * | 1973-08-23 | 1976-04-13 | Products International Marketing | Disposable speculum for tympanic thermometer |
US3878836A (en) * | 1973-08-23 | 1975-04-22 | Products Int Marketing | Disposable speculum for tympanic thermometer |
US3958560A (en) * | 1974-11-25 | 1976-05-25 | Wayne Front March | Non-invasive automatic glucose sensor system |
US4014321A (en) * | 1974-11-25 | 1977-03-29 | March Wayne F | Non-invasive glucose sensor system |
NL7415905A (en) * | 1974-12-06 | 1976-06-09 | Akzo Nv | METHOD AND DEVICE FOR CUTTING FIBERS. |
CA1037285A (en) * | 1975-04-30 | 1978-08-29 | Glenfield Warner | Ear oximetry process and apparatus |
DE2606991A1 (en) * | 1976-02-20 | 1977-08-25 | Nils Dr Med Kaiser | DEVICE FOR DETERMINING THE CONTENT OF METABOLIC PRODUCTS IN THE BLOOD |
US4281645A (en) * | 1977-06-28 | 1981-08-04 | Duke University, Inc. | Method and apparatus for monitoring metabolism in body organs |
US4195641A (en) * | 1977-12-15 | 1980-04-01 | Burton Larry W | Spectroscopic analysis of chemical substances |
GB2033575B (en) * | 1978-05-24 | 1983-03-02 | Rolfe P | Investigating substances in a patient's bloodstream |
US4281646A (en) * | 1978-06-30 | 1981-08-04 | Olympus Optical Co., Ltd. | Cleaning device for an observation window of an endoscope |
US4344438A (en) * | 1978-08-02 | 1982-08-17 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Optical sensor of plasma constituents |
US4265250A (en) * | 1979-07-23 | 1981-05-05 | Battle Research And Development Associates | Electrode |
DE2934190A1 (en) * | 1979-08-23 | 1981-03-19 | Müller, Gerhard, Prof. Dr.-Ing., 7080 Aalen | METHOD AND DEVICE FOR MOLECULAR SPECTROSCOPY, ESPECIALLY FOR DETERMINING METABOLISM PRODUCTS |
US4407290A (en) * | 1981-04-01 | 1983-10-04 | Biox Technology, Inc. | Blood constituent measuring device and method |
JPS58113807A (en) * | 1981-12-28 | 1983-07-06 | Canon Inc | Distance measuring device |
US4476870A (en) * | 1982-03-30 | 1984-10-16 | The United States Of America As Represented By The Department Of Health And Human Services | Fiber optic PO.sbsb.2 probe |
US4622974A (en) * | 1984-03-07 | 1986-11-18 | University Of Tennessee Research Corporation | Apparatus and method for in-vivo measurements of chemical concentrations |
ATE42673T1 (en) * | 1984-05-04 | 1989-05-15 | Kurashiki Boseki Kk | SPECTROPHOTOMETRIC DEVICE FOR THE BLOOD-FREE DETERMINATION OF GLUCOSE IN LIVING TISSUE. |
US4602642A (en) * | 1984-10-23 | 1986-07-29 | Intelligent Medical Systems, Inc. | Method and apparatus for measuring internal body temperature utilizing infrared emissions |
US4790324A (en) * | 1984-10-23 | 1988-12-13 | Intelligent Medical Systems, Inc. | Method and apparatus for measuring internal body temperature utilizing infrared emissions |
US4662360A (en) * | 1984-10-23 | 1987-05-05 | Intelligent Medical Systems, Inc. | Disposable speculum |
US4655225A (en) * | 1985-04-18 | 1987-04-07 | Kurabo Industries Ltd. | Spectrophotometric method and apparatus for the non-invasive |
US4750830A (en) * | 1985-11-29 | 1988-06-14 | Lee Arnold St J | Method and apparatus for monitoring blood-glucose concentration by measuring focal properties of the eye |
US4772561A (en) * | 1985-12-23 | 1988-09-20 | Miles Inc. | Test device and method of determining concentration of a sample component |
US4704029A (en) * | 1985-12-26 | 1987-11-03 | Research Corporation | Blood glucose monitor |
US4685463A (en) * | 1986-04-03 | 1987-08-11 | Williams R Bruce | Device for continuous in vivo measurement of blood glucose concentrations |
JPS6323645A (en) * | 1986-05-27 | 1988-01-30 | 住友電気工業株式会社 | Reflection heating type oxymeter |
DE3619442A1 (en) * | 1986-06-10 | 1987-12-17 | Holzer Walter | Blood analysis device |
US4800886A (en) * | 1986-07-14 | 1989-01-31 | C. R. Bard, Inc. | Sensor for measuring the concentration of a gaseous component in a fluid by absorption |
US4805623A (en) * | 1987-09-04 | 1989-02-21 | Vander Corporation | Spectrophotometric method for quantitatively determining the concentration of a dilute component in a light- or other radiation-scattering environment |
US4854699A (en) * | 1987-11-02 | 1989-08-08 | Nippon Colin Co., Ltd. | Backscatter oximeter |
US4882492A (en) * | 1988-01-19 | 1989-11-21 | Biotronics Associates, Inc. | Non-invasive near infrared measurement of blood analyte concentrations |
US4850365A (en) * | 1988-03-14 | 1989-07-25 | Futrex, Inc. | Near infrared apparatus and method for determining percent fat in a body |
US4901728A (en) * | 1988-05-31 | 1990-02-20 | Eol, Inc. | Personal glucose monitor |
DK45889D0 (en) * | 1989-02-01 | 1989-02-01 | Medicoteknisk Inst | PROCEDURE FOR HEARING ADJUSTMENT |
DE3910749A1 (en) * | 1989-04-03 | 1990-10-04 | Hellige Gmbh | Method and device for the non-invasive monitoring of physiological parameters |
-
1990
- 1990-04-19 US US07/510,935 patent/US5115133A/en not_active Expired - Lifetime
-
1991
- 1991-04-12 AU AU77893/91A patent/AU7789391A/en not_active Abandoned
- 1991-04-12 EP EP91909226A patent/EP0525112A1/en not_active Withdrawn
- 1991-04-12 CA CA002080472A patent/CA2080472A1/en not_active Abandoned
- 1991-04-12 WO PCT/US1991/002546 patent/WO1991015990A1/en not_active Application Discontinuation
- 1991-04-12 JP JP91508616A patent/JPH05506171A/en active Pending
- 1991-12-20 US US07/812,565 patent/US5179951A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU7789391A (en) | 1991-11-11 |
US5179951A (en) | 1993-01-19 |
JPH05506171A (en) | 1993-09-16 |
WO1991015990A1 (en) | 1991-10-31 |
EP0525112A1 (en) | 1993-02-03 |
US5115133A (en) | 1992-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5179951A (en) | Blood constituent measurement | |
US5146091A (en) | Body fluid constituent measurement utilizing an interference pattern | |
US5137023A (en) | Method and apparatus for monitoring blood analytes noninvasively by pulsatile photoplethysmography | |
JP3212996B2 (en) | Apparatus for measuring blood glucose level in a living body | |
CA2171640C (en) | Non-invasive blood analyte sensor | |
JP2965212B2 (en) | Method and apparatus for determining the similarity of biological analytes from models made from known biological fluids | |
US6662031B1 (en) | Method and device for the noninvasive determination of hemoglobin and hematocrit | |
US5460177A (en) | Method for non-invasive measurement of concentration of analytes in blood using continuous spectrum radiation | |
JP3210632B2 (en) | Apparatus for non-invasive measurement of blood glucose by photoacoustic | |
CA2189754C (en) | Self-emission noninvasive infrared spectrophotometer | |
US8326390B2 (en) | Optical non-invasive blood monitoring system and method | |
ES2344278T3 (en) | MEASUREMENT OF THE CONCENTRATION OF GLUCOSE IN PULSING BLOOD. | |
US6002953A (en) | Non-invasive IR transmission measurement of analyte in the tympanic membrane | |
US8886268B2 (en) | Living body information measuring apparatus | |
US6097975A (en) | Apparatus and method for noninvasive glucose measurement | |
PL184077B1 (en) | Method of monitoring constituents of tissue by means of ir radiation | |
US7486976B1 (en) | Optical non-invasive blood monitoring system and method | |
JPS6157774B2 (en) | ||
KR100300960B1 (en) | Method and device for noninvasive determination of the concentrations of blood components | |
WO2010033104A1 (en) | Optical non-invasive blood monitoring system and method | |
KR20020037867A (en) | System for monitoring body fluid constituents comprising reflective optics in living body tissue and method for monitoring body fluid constituents using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |